Mein Warenkorb

Galectin-9

Galectin-9 Molekülinformation

Englischer NameGalactoside-binding lectin Galectin 9Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel2Target-AliasEcalectin,Tumor antigen HOM-HD-21,Galectin-9,Lectin, Galactoside-Binding, Soluble, 9,LGALS9
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Englischer NameGalactoside-binding lectin Galectin 9
Target-AliasEcalectin,Tumor antigen HOM-HD-21,Galectin-9,Lectin, Galactoside-Binding, Soluble, 9,LGALS9
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel2
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical

Galectin-9 Produktliste

  • Attribut

    Protein (3)

  • Produktbibliothek

    Online (3)

  • Spezies

    Human (3)

  • Etikett

    His Tag (1)His Tag & Avi Tag (1)Tag Free (1)

  • Marker

    Unconjugated (2)Biotin-labeled (1)

Galectin-9 Molekülhintergrund

Galectin-9 (LGALS9) is also known as tumor antigen HOM-HD-21 and ecalectin. Galectins are a family of proteins defined by their binding specificity for β-galactoside sugars, such as N-acetyllactosamine (Galβ1-3GlcNAc or Galβ1-4GlcNAc), which can be bound to proteins by either N-linked or O-linked glycosylation. As for Galectin-9, it has high affinity for the Forssman pentasaccharide, and it is also the ligand for HAVCR2/TIM3. Forthermore, Galectin-9 stimulates bactericidal activity in infected macrophages by causing macrophage activation and IL1B secretion which restricts intracellular bacterial growth.

Galectin-9 Molekülalias

Galectin-9,LGALS9,Ecalectin

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
LYT-200LYT-200Phase 2 ClinicalPuretech HealthSolid tumours; Head and Neck Neoplasms; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Myelodysplastic Syndromes; Cholangiocarcinoma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Neoplasm Metastasis
Details
Anti-Gal9 antibody (Fibrogen)FG-3165; HFB-200901; HFB-200902; HFB2009; HFB2009 series; HFB9-2Phase 1 ClinicalHiFiBiO TherapeuticsSolid tumours
Details
  • Molekülinformation
  • Produktliste
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns